Cargando…

Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities

BACKGROUND: The tumor immune microenvironment of lepidic-pattern adenocarcinoma remains poorly understood. In this study, we characterized tumor infiltrating lymphocytes (TILs) and percent PD-L1 expression among adenocarcinoma presenting as either radiographic ground glass opacities (GGOs) or solid...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, David B., Mitchell, Kyle G., Wang, Jing, Fujimoto, Junya, Godoy, Myrna, Behrens, Carmen, Zheng, Xiaofeng, Zhang, Jianjun, Sepesi, Boris, Vaporciyan, Ara A., Hofstetter, Wayne L., Mehran, Reza J., Rice, David C., Walsh, Garrett L., Swisher, Stephen G., Moran, Cesar A., Kalhor, Neda, Weissferdt, Annikka, Wistuba, Ignacio I., Roth, Jack A., Antonoff, Mara B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139029/
https://www.ncbi.nlm.nih.gov/pubmed/32274099
http://dx.doi.org/10.21037/jtd.2020.01.42
_version_ 1783518674697584640
author Nelson, David B.
Mitchell, Kyle G.
Wang, Jing
Fujimoto, Junya
Godoy, Myrna
Behrens, Carmen
Zheng, Xiaofeng
Zhang, Jianjun
Sepesi, Boris
Vaporciyan, Ara A.
Hofstetter, Wayne L.
Mehran, Reza J.
Rice, David C.
Walsh, Garrett L.
Swisher, Stephen G.
Moran, Cesar A.
Kalhor, Neda
Weissferdt, Annikka
Wistuba, Ignacio I.
Roth, Jack A.
Antonoff, Mara B.
author_facet Nelson, David B.
Mitchell, Kyle G.
Wang, Jing
Fujimoto, Junya
Godoy, Myrna
Behrens, Carmen
Zheng, Xiaofeng
Zhang, Jianjun
Sepesi, Boris
Vaporciyan, Ara A.
Hofstetter, Wayne L.
Mehran, Reza J.
Rice, David C.
Walsh, Garrett L.
Swisher, Stephen G.
Moran, Cesar A.
Kalhor, Neda
Weissferdt, Annikka
Wistuba, Ignacio I.
Roth, Jack A.
Antonoff, Mara B.
author_sort Nelson, David B.
collection PubMed
description BACKGROUND: The tumor immune microenvironment of lepidic-pattern adenocarcinoma remains poorly understood. In this study, we characterized tumor infiltrating lymphocytes (TILs) and percent PD-L1 expression among adenocarcinoma presenting as either radiographic ground glass opacities (GGOs) or solid lesions. METHODS: Pathologic specimens of patients with clinical stage I lung adenocarcinoma were analyzed using tissue microarray sectioning. The invasive portion of the tumor was selected for the tissue core. Lepidic growth pattern was confirmed among the GGO lesions using whole section analysis. Progression was defined as pN+ or subsequent recurrence. RESULTS: A total of 181 patients were identified, among whom 13 (7%) represented GGOs without clinical progression, 113 (62%) represented radiographic solid lesions that never progressed, and 55 (30%) represented radiographic solid lesions that ultimately did progress. CD57+ cell density, a marker for antigen-specific, oligoclonal T cells and NK cells, differed among the three cohorts, with the highest cell density observed within radiographically solid lesions without progression, and lower cell density both in the radiographic solid lesions that progressed and GGOs. Other TIL phenotypes were not statistically different between cohorts. Of substantial clinical interest, median percent PD-L1 positive cells within GGOs was 14, whereas that of radiographic solid lesions without progression was 22, and radiographic solid lesions that subsequently progressed was 27 (P=0.07). CONCLUSIONS: Lepidic pattern adenocarcinoma presenting as GGOs and radiographic solid lesions show differential immune regulation. Further studies to investigate whether GGOs representing adenocarcinoma have varying susceptibility to immune checkpoint inhibitor therapy are warranted.
format Online
Article
Text
id pubmed-7139029
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-71390292020-04-09 Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities Nelson, David B. Mitchell, Kyle G. Wang, Jing Fujimoto, Junya Godoy, Myrna Behrens, Carmen Zheng, Xiaofeng Zhang, Jianjun Sepesi, Boris Vaporciyan, Ara A. Hofstetter, Wayne L. Mehran, Reza J. Rice, David C. Walsh, Garrett L. Swisher, Stephen G. Moran, Cesar A. Kalhor, Neda Weissferdt, Annikka Wistuba, Ignacio I. Roth, Jack A. Antonoff, Mara B. J Thorac Dis Original Article BACKGROUND: The tumor immune microenvironment of lepidic-pattern adenocarcinoma remains poorly understood. In this study, we characterized tumor infiltrating lymphocytes (TILs) and percent PD-L1 expression among adenocarcinoma presenting as either radiographic ground glass opacities (GGOs) or solid lesions. METHODS: Pathologic specimens of patients with clinical stage I lung adenocarcinoma were analyzed using tissue microarray sectioning. The invasive portion of the tumor was selected for the tissue core. Lepidic growth pattern was confirmed among the GGO lesions using whole section analysis. Progression was defined as pN+ or subsequent recurrence. RESULTS: A total of 181 patients were identified, among whom 13 (7%) represented GGOs without clinical progression, 113 (62%) represented radiographic solid lesions that never progressed, and 55 (30%) represented radiographic solid lesions that ultimately did progress. CD57+ cell density, a marker for antigen-specific, oligoclonal T cells and NK cells, differed among the three cohorts, with the highest cell density observed within radiographically solid lesions without progression, and lower cell density both in the radiographic solid lesions that progressed and GGOs. Other TIL phenotypes were not statistically different between cohorts. Of substantial clinical interest, median percent PD-L1 positive cells within GGOs was 14, whereas that of radiographic solid lesions without progression was 22, and radiographic solid lesions that subsequently progressed was 27 (P=0.07). CONCLUSIONS: Lepidic pattern adenocarcinoma presenting as GGOs and radiographic solid lesions show differential immune regulation. Further studies to investigate whether GGOs representing adenocarcinoma have varying susceptibility to immune checkpoint inhibitor therapy are warranted. AME Publishing Company 2020-03 /pmc/articles/PMC7139029/ /pubmed/32274099 http://dx.doi.org/10.21037/jtd.2020.01.42 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Nelson, David B.
Mitchell, Kyle G.
Wang, Jing
Fujimoto, Junya
Godoy, Myrna
Behrens, Carmen
Zheng, Xiaofeng
Zhang, Jianjun
Sepesi, Boris
Vaporciyan, Ara A.
Hofstetter, Wayne L.
Mehran, Reza J.
Rice, David C.
Walsh, Garrett L.
Swisher, Stephen G.
Moran, Cesar A.
Kalhor, Neda
Weissferdt, Annikka
Wistuba, Ignacio I.
Roth, Jack A.
Antonoff, Mara B.
Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities
title Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities
title_full Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities
title_fullStr Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities
title_full_unstemmed Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities
title_short Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities
title_sort immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139029/
https://www.ncbi.nlm.nih.gov/pubmed/32274099
http://dx.doi.org/10.21037/jtd.2020.01.42
work_keys_str_mv AT nelsondavidb immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT mitchellkyleg immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT wangjing immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT fujimotojunya immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT godoymyrna immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT behrenscarmen immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT zhengxiaofeng immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT zhangjianjun immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT sepesiboris immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT vaporciyanaraa immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT hofstetterwaynel immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT mehranrezaj immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT ricedavidc immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT walshgarrettl immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT swisherstepheng immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT morancesara immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT kalhorneda immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT weissferdtannikka immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT wistubaignacioi immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT rothjacka immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities
AT antonoffmarab immuneregulatorymarkersoflepidicpatternadenocarcinomaspresentingasgroundglassopacities